Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company developing targeted immunotherapies for rare and serious diseases. The company's proprietary Synthetic Vaccine Particle (SVP?) technology platform enables the design of antigen-specific immunotherapies that induce antigen-specific immune responses. Selecta's lead program, SEL-212, is a combination therapy for the treatment of chronic refractory gout. The company is also developing therapies for rare genetic diseases, including methylmalonic acidemia and ornithine transcarbamylase deficiency. Selecta Biosciences is headquartered in Lexington, Massachusetts.